April 22, 2026Open Access

Benefit of revascularization for stable ischaemic heart disease: the jury is still out

Resultado clave

Revascularization for stable ischemic heart disease currently lacks definitive evidence of clinical benefit.

Puntos clave

To evaluate the benefits of revascularization in patients with stable ischaemic heart disease and its implications for treatment decisions.
Randomized trial
Comparison of revascularization versus medical management
Assessment of clinical outcomes
No significant improvement in quality of life scores post-intervention
Mortality rates were similar between revascularization and medical management groups
Cardiovascular risk factors remained consistent across treatment groups

PICO estructurado

Does revascularization improve outcomes compared to optimal medical therapy in patients with stable ischaemic heart disease?

Población

Patients with stable ischaemic heart disease (SIHD)

Intervención

Revascularization (percutaneous coronary intervention or coronary artery bypass grafting)

Comparador

Optimal medical therapy (OMT) alone

The benefit of revascularization over optimal medical therapy in stable ischemic heart disease remains debated due to conflicting results between older observational data and modern randomized trials.

Resultado numérico

Tasa de eventos absoluta: 0% vs 0%

Resumen

peer reviewed

Me gusta

Guardar

Ver artículo completo

Cite This Study

Fassa et al. (Tue,) reported a other. Revascularization for stable ischemic heart disease currently lacks definitive evidence of clinical benefit.

synapsesocial.com/papers/69e8e6ef5169eb7de91c9213 https://doi.org/https://doi.org/10.1093/eurheartj/eht004

Me gusta

Guardar

Ver artículo completo